Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30298595 | 1.00 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CP2RY6MIF | |
| SCHEMBL1026501 | 0.79 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CPIK3CDNAPRT | |
| SCHEMBL21518466 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CP2RY6MIF | |
| SCHEMBL30298656 | 0.75 | P2RY6 (0.42) | P2RY6MIFCA1CA2CYP2A6 | |
| SCHEMBL1421304 | 0.75 | P2RY6 (0.42) | P2RY6MIFCA1CA2CYP2A6 | |
| SCHEMBL30298639 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CP2RY6MIF | |
| SCHEMBL22117779 | 0.73 | P2RY6 (0.41) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL11711212 | 0.72 | L3MBTL1 (0.42) | P2RY6MIFHSD17B10 | |
| SCHEMBL22115413 | 0.71 | — | — | |
| SCHEMBL11955561 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701635-A1 | 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS | Universitat De Barcelona (ES) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024223907-A1 | 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS | UNIVERSITAT DE BARCELONA (ES) | 2024-10-31 | — | — | WO | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-109824603-B | Pyrimidinamine compound, preparation method and application thereof | 浙江省化工研究院有限公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-2578584-B1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SI CHUAN UNIV (CN) | 2020-08-12 | — | — | EP | disclosed |
| EP-1198456-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070078131-A1 | Thieno-pyridinone derivatives as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2007-04-05 | — | — | US | disclosed |
| EP-1680429-A1 | THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS | Celltech R & D Limited (GB) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005042540-A1 | THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| EP-1392655-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6645968-B2 | E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; | ABBOTT LABORATORIES | 2003-11-11 | — | — | US | disclosed |
| WO-2002062762-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1198456-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | ADRA2A 1214/4885ADRA2B 1500/4885ADRA2C 1353/4885 |
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | ADRA2A 1403/4885ADRA2B 2085/4885ADRA2C 1464/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | ADRA2A 1214/4885ADRA2B 1500/4885ADRA2C 1353/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | ADRA2A 1214/4885ADRA2B 1500/4885ADRA2C 1353/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | ADRA2A 2408/4885ADRA2B 1996/4885ADRA2C 1613/4885 |
| US-20070078131-A1 | Thieno-pyridinone derivatives as kinase inhibitors | MAP3K6, MAP4K2, MAP3K15 | ADRA2A 1793/4885ADRA2B 1136/4885ADRA2C 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.